Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.51 |
| ▸ | STAT6 | P42226 | 6/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524290 | 0.91 | SYK (0.47) | SYKSTAT6CDK4CCND1CCNK | |
| SCHEMBL15524080 | 0.90 | CCND3 (0.58) | SYKSTAT6CDK4CCND1CCNK | |
| SCHEMBL12478740 | 0.88 | PTK2 (0.53) | SYKSTAT6CDK4CCND1 | |
| SCHEMBL15524392 | 0.87 | STAT6 (0.50) | SYKSTAT6 | |
| SCHEMBL15524487 | 0.85 | STAT6 (0.44) | SYKSTAT6 | |
| SCHEMBL15524377 | 0.85 | CAMK2D (0.43) | SYKSTAT6CDK4CDK2 | |
| SCHEMBL15524674 | 0.84 | FLT4 (0.47) | SYKSTAT6 | |
| SCHEMBL15524227 | 0.82 | CCND3 (0.58) | SYKSTAT6CDK4CCND1CCNK | |
| SCHEMBL15524600 | 0.82 | FLT4 (0.48) | CDK2CDK9 | |
| SCHEMBL15524831 | 0.81 | EGFR (0.46) | STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | SYK 126/4885STAT6 4087/4885CDK4 46/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | SYK 171/4885STAT6 3580/4885CDK4 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.